Related Experiment Video
Updated: Nov 3, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Moderate Aortic Stenosis in Patients With Heart Failure and Reduced Ejection Fraction
Guillaume Jean1, Nicolas M Van Mieghem2, Tea Gegenava3
1Institut universitaire de cardiologie et de pneumologie, Université Laval, Québec, Québec, Canada.
Insights
Moderate aortic stenosis (AS) significantly increases mortality risk in heart failure with reduced ejection fraction (HFrEF) patients. Aortic valve replacement, particularly transcatheter AVR, improves survival in this population.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Heart Failure Research
Background:
- Moderate aortic stenosis (AS) is linked to poor prognosis in heart failure with reduced left ventricular ejection fraction (HFrEF).
- The independent impact of moderate AS versus HFrEF on patient outcomes remains unclear.
Purpose of the Study:
- To investigate the effect of moderate AS on mortality and heart failure hospitalization in patients with HFrEF.
- To assess the impact of aortic valve replacement (AVR) on survival in this patient cohort.
Main Methods:
- Matched cohort study comparing 262 patients with HFrEF and moderate AS to 262 patients with HFrEF and no AS.
- Patients were matched for key clinical characteristics including LVEF, NYHA class, and comorbidities.
- Primary endpoints included all-cause mortality and a composite of death and HF hospitalization.
Main Results:
- Moderate AS was associated with a nearly threefold increased risk of mortality (HR: 2.98) and a 2.3-fold increased risk for the composite endpoint.
- Aortic valve replacement (AVR) during follow-up was linked to improved survival (HR: 0.59).
- Transcatheter AVR showed a significant survival benefit (HR: 0.43), while surgical AVR did not reach statistical significance.
Conclusions:
- Moderate AS significantly elevates mortality risk in patients with HFrEF.
- Aortic valve replacement, especially transcatheter AVR, improves survival in HFrEF patients with moderate AS.
- Findings support a randomized trial for early transcatheter AVR in this population.
Background:
The study investigators previously reported that moderate aortic stenosis (AS) is associated with a poor prognosis in patients with heart failure (HF) with reduced left ventricular ejection fraction (LVEF) (HFrEF). However, the respective contribution of moderate AS versus HFrEF to the outcomes of these patients is unknown.
Objectives:
This study sought to determine the impact of moderate AS on outcomes in patients with HFrEF.
Methods:
The study included 262 patients with moderate AS (aortic valve area >1.0 and <1.5 cm2; and peak aortic jet velocity >2 and <4 m/s, at rest or after dobutamine stress echocardiography) and HFrEF (LVEF <50%). These patients were matched 1:1 for sex, age, estimated glomerular filtration rate, New York Heart Association functional class III to IV, presence of diabetes, LVEF, and body mass index with patients with HFrEF but no AS (i.e., peak aortic jet velocity <2 m/s). The endpoints were all-cause mortality and the composite of death and HF hospitalization.
Results:
A total of 262 patients with HFrEF and moderate AS were matched with 262 patients with HFrEF and no AS. Mean follow-up was 2.9 ± 2.2 years. In the moderate AS group, mean aortic valve area was 1.2 ± 0.2 cm2, and mean gradient was 14.5 ± 4.7 mm Hg. Moderate AS was associated with an increased risk of mortality (hazard ratio [HR]: 2.98; 95% confidence interval [CI]: 2.08 to 4.31; p < 0.0001) and of the composite of HF hospitalization and mortality (HR: 2.34; 95% CI: 1. 72 to 3.21; p < 0.0001). In the moderate AS group, aortic valve replacement (AVR) performed in 44 patients at a median follow-up time of 10.9 ± 16 months during follow-up was associated with improved survival (HR: 0.59; 95% CI: 0.35 to 0.98; p = 0.04). Notably, surgical AVR was not significantly associated with improved survival (p = 0.92), whereas transcatheter AVR was (HR: 0.43; 95% CI: 0.18 to 1.00; p = 0.05).
Conclusions:
In this series of patients with HFrEF, moderate AS was associated with a marked incremental risk of mortality. AVR, and especially transcatheter AVR during follow-up, was associated with improved survival in patients with HFrEF and moderate AS. These findings provide support to the realization of a randomized trial to assess the effect of early transcatheter AVR in patients with HFrEF and moderate AS.
More Related Videos
Related Concept Videos
Heart Failure V: Medical Management
Aortic Regurgitation III: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Mitral Stenosis IV: Nursing Management
Mitral Stenosis III: Medical Management

